EMPA-REG OUTCOME: The Cardiologist's Point of View

Son V. Pham, Robert J Chilton

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report.

Original languageEnglish (US)
Pages (from-to)S53-S58
JournalAmerican Journal of Cardiology
Volume120
Issue number1
DOIs
StatePublished - Jul 1 2017

Fingerprint

Type 2 Diabetes Mellitus
Cardiovascular Physiological Phenomena
Cardiovascular Agents
Workload
Oxygen Consumption
Hyperglycemia
Compliance
Arterial Pressure
Hospitalization
Heart Failure
Glucose
empagliflozin
Cardiologists

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

EMPA-REG OUTCOME : The Cardiologist's Point of View. / Pham, Son V.; Chilton, Robert J.

In: American Journal of Cardiology, Vol. 120, No. 1, 01.07.2017, p. S53-S58.

Research output: Contribution to journalArticle

Pham, Son V. ; Chilton, Robert J. / EMPA-REG OUTCOME : The Cardiologist's Point of View. In: American Journal of Cardiology. 2017 ; Vol. 120, No. 1. pp. S53-S58.
@article{54784ab354be42e18b8effc29407f712,
title = "EMPA-REG OUTCOME: The Cardiologist's Point of View",
abstract = "Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report.",
author = "Pham, {Son V.} and Chilton, {Robert J}",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.amjcard.2017.05.011",
language = "English (US)",
volume = "120",
pages = "S53--S58",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - EMPA-REG OUTCOME

T2 - The Cardiologist's Point of View

AU - Pham, Son V.

AU - Chilton, Robert J

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report.

AB - Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report.

UR - http://www.scopus.com/inward/record.url?scp=85020395878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020395878&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2017.05.011

DO - 10.1016/j.amjcard.2017.05.011

M3 - Article

C2 - 28606345

AN - SCOPUS:85020395878

VL - 120

SP - S53-S58

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 1

ER -